List of Tables
Table 1. Influenza Antiviral Drugs Market Trends
Table 2. Influenza Antiviral Drugs Market Drivers & Opportunity
Table 3. Influenza Antiviral Drugs Market Challenges
Table 4. Influenza Antiviral Drugs Market Restraints
Table 5. Global Influenza Antiviral Drugs Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Influenza Antiviral Drugs Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Influenza Antiviral Drugs Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Influenza Antiviral Drugs Product Type
Table 9. Key Companies Time to Begin Mass Production of Influenza Antiviral Drugs
Table 10. Global Influenza Antiviral Drugs Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Antiviral Drugs as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Influenza Antiviral Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Influenza Antiviral Drugs Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Influenza Antiviral Drugs Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Influenza Antiviral Drugs Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Influenza Antiviral Drugs Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Influenza Antiviral Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Influenza Antiviral Drugs Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Influenza Antiviral Drugs Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Influenza Antiviral Drugs Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Influenza Antiviral Drugs Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Influenza Antiviral Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Influenza Antiviral Drugs Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Influenza Antiviral Drugs Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Influenza Antiviral Drugs Sales Value by Region (2019-2024) & (%)
Table 27. Global Influenza Antiviral Drugs Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Influenza Antiviral Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Influenza Antiviral Drugs Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Influenza Antiviral Drugs Sales Value, (2025-2030) & (US$ Million)
Table 31. GSK Basic Information List
Table 32. GSK Description and Business Overview
Table 33. GSK Influenza Antiviral Drugs Products, Services and Solutions
Table 34. Revenue (US$ Million) in Influenza Antiviral Drugs Business of GSK (2019-2024)
Table 35. GSK Recent Developments
Table 36. Boehringer Ingelheim Basic Information List
Table 37. Boehringer Ingelheim Description and Business Overview
Table 38. Boehringer Ingelheim Influenza Antiviral Drugs Products, Services and Solutions
Table 39. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Boehringer Ingelheim (2019-2024)
Table 40. Boehringer Ingelheim Recent Developments
Table 41. Merck Basic Information List
Table 42. Merck Description and Business Overview
Table 43. Merck Influenza Antiviral Drugs Products, Services and Solutions
Table 44. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Merck (2019-2024)
Table 45. Merck Recent Developments
Table 46. Novartis Basic Information List
Table 47. Novartis Description and Business Overview
Table 48. Novartis Influenza Antiviral Drugs Products, Services and Solutions
Table 49. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Novartis (2019-2024)
Table 50. Novartis Recent Developments
Table 51. Beximco Pharmaceuticals Basic Information List
Table 52. Beximco Pharmaceuticals Description and Business Overview
Table 53. Beximco Pharmaceuticals Influenza Antiviral Drugs Products, Services and Solutions
Table 54. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Beximco Pharmaceuticals (2019-2024)
Table 55. Beximco Pharmaceuticals Recent Developments
Table 56. Pfizer Basic Information List
Table 57. Pfizer Description and Business Overview
Table 58. Pfizer Influenza Antiviral Drugs Products, Services and Solutions
Table 59. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Pfizer (2019-2024)
Table 60. Pfizer Recent Developments
Table 61. Roche Basic Information List
Table 62. Roche Description and Business Overview
Table 63. Roche Influenza Antiviral Drugs Products, Services and Solutions
Table 64. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Roche (2019-2024)
Table 65. Roche Recent Developments
Table 66. Johnson & Johnson Basic Information List
Table 67. Johnson & Johnson Description and Business Overview
Table 68. Johnson & Johnson Influenza Antiviral Drugs Products, Services and Solutions
Table 69. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Johnson & Johnson (2019-2024)
Table 70. Johnson & Johnson Recent Developments
Table 71. Sanofi Basic Information List
Table 72. Sanofi Description and Business Overview
Table 73. Sanofi Influenza Antiviral Drugs Products, Services and Solutions
Table 74. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Sanofi (2019-2024)
Table 75. Sanofi Recent Developments
Table 76. Cipla Limited Basic Information List
Table 77. Cipla Limited Description and Business Overview
Table 78. Cipla Limited Influenza Antiviral Drugs Products, Services and Solutions
Table 79. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Cipla Limited (2019-2024)
Table 80. Cipla Limited Recent Developments
Table 81. Natco Pharma Basic Information List
Table 82. Natco Pharma Description and Business Overview
Table 83. Natco Pharma Influenza Antiviral Drugs Products, Services and Solutions
Table 84. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Natco Pharma (2019-2024)
Table 85. Natco Pharma Recent Developments
Table 86. Seqirus Basic Information List
Table 87. Seqirus Description and Business Overview
Table 88. Seqirus Influenza Antiviral Drugs Products, Services and Solutions
Table 89. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Seqirus (2019-2024)
Table 90. Seqirus Recent Developments
Table 91. Adamas Pharmaceuticals, Inc. Basic Information List
Table 92. Adamas Pharmaceuticals, Inc. Description and Business Overview
Table 93. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Products, Services and Solutions
Table 94. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Adamas Pharmaceuticals, Inc. (2019-2024)
Table 95. Adamas Pharmaceuticals, Inc. Recent Developments
Table 96. Teva Pharmaceuticals Basic Information List
Table 97. Teva Pharmaceuticals Description and Business Overview
Table 98. Teva Pharmaceuticals Influenza Antiviral Drugs Products, Services and Solutions
Table 99. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Teva Pharmaceuticals (2019-2024)
Table 100. Teva Pharmaceuticals Recent Developments
Table 101. Daiichi Sankyo Company Basic Information List
Table 102. Daiichi Sankyo Company Description and Business Overview
Table 103. Daiichi Sankyo Company Influenza Antiviral Drugs Products, Services and Solutions
Table 104. Revenue (US$ Million) in Influenza Antiviral Drugs Business of Daiichi Sankyo Company (2019-2024)
Table 105. Daiichi Sankyo Company Recent Developments
Table 106. Key Raw Materials Lists
Table 107. Raw Materials Key Suppliers Lists
Table 108. Influenza Antiviral Drugs Downstream Customers
Table 109. Influenza Antiviral Drugs Distributors List
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
Table 113. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Influenza Antiviral Drugs Product Picture
Figure 2. Global Influenza Antiviral Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Influenza Antiviral Drugs Sales Value (2019-2030) & (US$ Million)
Figure 4. Influenza Antiviral Drugs Report Years Considered
Figure 5. Global Influenza Antiviral Drugs Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Influenza Antiviral Drugs Revenue in 2023
Figure 7. Influenza Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Oseltamivir Picture
Figure 9. Zanamivir Picture
Figure 10. Peramivir Picture
Figure 11. Adamantanes Picture
Figure 12. Others Picture
Figure 13. Global Influenza Antiviral Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Influenza Antiviral Drugs Sales Value Market Share by Type, 2023 & 2030
Figure 15. Product Picture of Hospitals
Figure 16. Product Picture of Clinics
Figure 17. Product Picture of Ambulatory Surgical Centers
Figure 18. Product Picture of Pharmacies
Figure 19. Product Picture of Others
Figure 20. Global Influenza Antiviral Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Influenza Antiviral Drugs Sales Value Market Share by Application, 2023 & 2030
Figure 22. North America Influenza Antiviral Drugs Sales Value (2019-2030) & (US$ Million)
Figure 23. North America Influenza Antiviral Drugs Sales Value by Country (%), 2023 VS 2030
Figure 24. Europe Influenza Antiviral Drugs Sales Value (2019-2030) & (US$ Million)
Figure 25. Europe Influenza Antiviral Drugs Sales Value by Country (%), 2023 VS 2030
Figure 26. Asia Pacific Influenza Antiviral Drugs Sales Value (2019-2030) & (US$ Million)
Figure 27. Asia Pacific Influenza Antiviral Drugs Sales Value by Country (%), 2023 VS 2030
Figure 28. South America Influenza Antiviral Drugs Sales Value (2019-2030) & (US$ Million)
Figure 29. South America Influenza Antiviral Drugs Sales Value by Country (%), 2023 VS 2030
Figure 30. Middle East & Africa Influenza Antiviral Drugs Sales Value (2019-2030) & (US$ Million)
Figure 31. Middle East & Africa Influenza Antiviral Drugs Sales Value by Country (%), 2023 VS 2030
Figure 32. Key Countries/Regions Influenza Antiviral Drugs Sales Value (%), (2019-2030)
Figure 33. United States Influenza Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 34. United States Influenza Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 35. United States Influenza Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 36. Europe Influenza Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 37. Europe Influenza Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 38. Europe Influenza Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 39. China Influenza Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 40. China Influenza Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 41. China Influenza Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 42. Japan Influenza Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 43. Japan Influenza Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 44. Japan Influenza Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 45. South Korea Influenza Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 46. South Korea Influenza Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 47. South Korea Influenza Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 48. Southeast Asia Influenza Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 49. Southeast Asia Influenza Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 50. Southeast Asia Influenza Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 51. India Influenza Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 52. India Influenza Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 53. India Influenza Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 54. Influenza Antiviral Drugs Industrial Chain
Figure 55. Influenza Antiviral Drugs Manufacturing Cost Structure
Figure 56. Channels of Distribution (Direct Sales, and Distribution)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
